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Abstract 
Multivariate prediction algorithms such as FRAX
®
 and QFractureScores provide an 
opportunity for new prognostic biomarkers to be developed and incorporated, potentially 
leading to better fracture prediction. As more research is conducted into these novel 
biomarkers, a number of factors need to be considered for their successful development for 
inclusion in these algorithms. This review paper describes two well-known multivariate 
prediction algorithms for osteoporosis fracture risk applicable to the UK population, FRAX 
and QFractureScores, and comments on the current prognostic tools available for fracture 
risk, dual x-ray assessment (DXA), quantitative ultrasound (QUS), genomic and biochemical 
markers and highlights the factors that need to be considered in the development of new 
biomarkers. These factors include the requirement for prospective data, collected in new 
cohort studies or using archived samples, the need for adequate stability data to be provided 
and appropriate storage methods to be used when retrospective data is required. AUC 
measures have been found to have limited utility in assessing the impact of the addition of 
new risk factors on the predictive performance multivariate algorithms. New performance 
evaluation measures, such as net reclassification index (NRI) and integrated discrimination 
improvement (IDI) are increasingly important in the evaluation of the impact of the addition 
of new markers to multivariate algorithms and these are also discussed. 
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Introduction 
 
The introduction of multivariate algorithm based fracture risk assessment tools such as FRAX
® 
has 
broadened the risk factors considered important for osteoporotic fracture risk [1]. These risk 
calculators are modifiable and therefore can incorporate appropriately validated new prognostic 
markers for fracture risk in the future. In particular, additional markers for bone quality factors which 
are linked to fracture risk would be beneficial [2]. Bone quality refers in part to the organic matrix of 
bone but also describes a set of characteristics that influence strength such as micro-architecture, re-
modelling and damage accumulation.   
 
Traditionally, osteoporosis has been defined using bone mineral density (BMD) as measured by T-
scores. In recent years there has been a move away from T-scores as the operating definition of 
osteoporosis, to the use of absolute risk of fracture and risk calculators based on algorithms to 
estimate those risks [3]. This movement has led to an evolved definition of the disease which 
incorporates more clinical risk factors (CRF) and which bases treatment decisions on absolute risk of 
fracture thresholds over a 10-year period rather than T-scores [3]. This paradigm shift brings 
osteoporosis into line with other conditions such as heart disease where patient risks are assessed on 
an absolute risk of event basis over a 10-year period [4]. This major change in the definition of 
osteoporosis creates an opportunity for new prognostic biomarkers to be identified and incorporated 
into risk assessment quickly and efficiently via the absolute risk approach once they meet the 
appropriate clinical evidence requirements. 
 
There is a need for improved prognostic factors in osteoporosis due to the increasing burden of 
fracture on the population and the resultant high mortality rates. Burge et al estimated that there were 
more than 2m fractures in the United States (US) in 2005, resulting in direct healthcare costs of $17bn 
[5]. The authors projected that this number would grow by 50% by 2025 due to the ageing of the 
population (“the grey tsunami”).  The number of fractures will reach over 3m a year at an annual cost 
of $25bn over the same time period [5]. It has been established that while incidence rates of hip 
fracture may be relatively low, excess mortality is significant, at between 8% and 36% compared with 
community based controls during the first year [6]. It has also been noted that it would be beneficial to 
treat women earlier than is current practice; ideally in the peri-menopausal stage when bone mass is 
near its lifetime peak, in order for the benefits of early preventative treatment to be realised [7]. The 
downside is that longer follow-up times may be needed than the currently standard 10-year period to 
conduct clinical trials which demonstrate the long-term benefits of early treatment.  
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This paper reviews the current state of the art and considers the steps required to develop a new 
prognostic marker with sufficient clinical evidence to justify inclusion in current fracture risk 
calculators. The review will include current risk factors and their evidence bases, methodologies for 
introducing new risk factors and new techniques available to evaluate their performance in terms of 
health and cost-effectiveness. 
 
Current Prognostic Fracture Risk Calculators  
 
The increased interest in regression model based risk calculators developed from established cohort 
studies has been driven by the need to develop more accurate models for who is likely to fracture and 
when  the fracture will occur. Another important issue is the lack of availability of dual energy x-ray 
assessment (DXA) machines in many countries. Also DXA performance is not optimal for detecting 
osteoporotic fracture risk due to poor predictive sensitivity, and therefore the use of additional CRFs 
in combination with DXA could help increase the sensitivity of diagnosis without impairing 
specificity [8].  Health economic evaluations have indicated that it is most effective to implement 
mass screening programmes using an initial assessment with CRFs followed by DXA evaluation in 
high risk subjects [9]. Mass screening can therefore be justified with the support of non-BMD 
prognostic markers to enhance overall prognostic performance in combination with DXA. Early work 
to combine clinical risk factors into prediction models for fracture risk to supplement DXA was 
conducted by Black et al [10]. Subsequent work has resulted in three validated fracture risk prediction 
models which are currently available online, FRAX, QFractureScores, and the Garvan model. The 
Garvan and Black models were developed in Australian and US populations respectively. The FRAX 
model is the most widely used currently. In order to provide an illustrative comparison, two of these 
models, FRAX and QFractureScores both of which are available for UK populations are described in 
more detail.  
 
FRAX 
 
The WHO Collaborating Centre for Metabolic Bone Diseases (University of Sheffield, Sheffield, UK) 
led by John Kanis developed the FRAX risk calculator to improve osteoporosis risk assessment. The 
algorithm, which uses a Poisson regression model to estimate risk, was developed with data from nine 
population cohorts and validated in another eleven cohorts comprising over one million patient years 
[7]. FRAX can calculate 10-year risk probabilities with or without the inclusion of femoral neck 
BMD. Table 1 shows the CRFs currently considered to have sufficient clinical evidence to justify 
their inclusion in FRAX.   
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There are a number of general and methodology-specific limitations in the FRAX initiative [8].  The 
calculator does not consider medications which influence fracture risk, and other factors such as falls 
risk and biochemical markers of bone turnover have been excluded due to the lack of large 
prospective studies validating their use. Additionally, risk factors are quantified in a binary fashion, 
rather than using multiple state options. A wide number of risk factors were considered for inclusion 
but only nine were felt to have sufficient evidence to justify their inclusion in the model [7].The 
developers consider FRAX to be a 'platform technology' into which new risk factors can be 
incorporated as they become available [3]. CRFs used in isolation do not predict fracture risk as 
strongly as a BMD measurement, however, CRFs in combination with BMD provide an enhanced 
predictive ability over BMD alone. 
 
Health screening modelling has demonstrated that the combined use of CRF and BMD in FRAX leads 
to a higher positive predictive value (PPV), a lower number of subjects required to treat to prevent 
one fracture and enhanced sensitivity in 55, 60 and 65 year olds over BMD alone [11]. This indicates 
that additional non-BMD prognostic factors could enhance the overall performance of predictive tools 
for fracture risk. The FRAX developers selected a 10-year horizon based partly on likely treatment 
duration and also on the limitations of the available clinical evidence as few relevant studies had more 
than 10 years of follow-up data [12]. However it may also be clinically useful to predict the 20-year or 
lifetime risks for younger women in order to earlier identify those who are significantly at risk of a 
fragility fracture in the future, which may be used to justify more regular screening which may result 
in non-pharmaceutical interventions and  lifestyle advice at an earlier stage for higher risk individuals. 
Early intervention at the peri-menopause could result in greater maintenance of bone mass and a 
reduction in the rate of loss in later life [13]. Barr et al have shown that screening for osteoporosis 
between the ages of 45–54 and following up with HRT treatment leads to reduced fracture incidence 
[14]. The incidence of hip fracture rises significantly in women aged between 70 and 90 years of age 
and clinical studies indicate that between these ages the prognostic performance of BMD as 
determined by DXA falls by more than the performance of CRFs [7]. There may therefore be an 
argument to focus on CRFs and exclude BMD as a risk factor when identifying elderly women who 
would benefit from treatment. 
 
The development and rapid acceptance of FRAX is an acknowledgement by the medical community 
of the importance of non-BMD risk factors in predicting osteoporotic fracture. The use of BMD 
within FRAX does improve prediction [11] but the identification of additional risk factors with 
potential to replace BMD would be beneficial to widen the use of osteoporosis screening, particularly 
in lower income countries where DXA is often unavailable. The advantage of including non-BMD 
based clinical risk factors which can be collected in a questionnaire format by a risk algorithm is that 
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these can be obtained at low cost and can add significantly to the prognostic power of BMD or in the 
absence of BMD can provide an acceptable decision-making tool for clinicians. 
 
Table 1: Clinical Risk Factors evaluated by the FRAX and QFractureScores algorithms 
   
Clinical Risk Factor FRAX QFractureScores 
Age X X 
Sex X X 
Weight X X 
Height X X 
Previous fracture X  
Parental hip fracture/osteoporosis X X 
Smoking X X 
Glucocorticoids* X X 
Rheumatoid arthritis X X 
Secondary osteoporosis** X  
Alcohol Intake X X 
Femoral neck BMD X  
Asthma  X 
Heart attack/Stroke  X 
Falls  X 
Chronic liver disease  X 
Tricyclic antidepressants  X 
Type 2 diabetes  X 
HRT  X 
Endocrine problem  X 
Malabsorption  X 
Menopausal symptoms  X 
     
 * In QFractureScores the use of “steroids” is recorded rather than glucocorticoids.   
** In QFractureScores secondary causes of osteoporosis are not recorded as a single entity, but are recorded 
separately as shown above. 
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QFractureScores  
 
The developers of the QFractureScores algorithm (www.qfracture.org) implemented a very different 
approach to the FRAX
 
developers. Their aim was to develop an algorithm that was prognostic without 
the requirement for diagnostic testing which introduces an external cost to the prevention programme. 
The QResearch database, a validated database of risk factors and outcome data collected from primary 
care practices in the UK was used to develop the algorithm [15]. This database contains the health 
records of over 11m people in England and Wales. The QResearch database contains information on 
1,174,232 men and 1,183,633 women, aged between 30 and 85 and 7,898,208 (female) and 8,049,306 
(male) observation years were used in developing the algorithm. In the female group, 24,350 incident 
fractures and 9,302 hip fractures were recorded. The risk factors assessed in the database are outlined 
in Table 1. 
 
The hazard ratios and coefficients in the model were derived using Cox’s proportional hazards 
regression model. To validate the QFractureScores model, hip fracture prognostic performance in a 
separate defined QResearch group was compared with the actual events over a 10 year period and 
with the predictions generated by FRAX in the same cohort. The validation group contained 653,789 
women and the average hip fracture incidence rate was 1.15% (1.13–1.17) [15]. QFractureScores has 
also been externally validated in a UK based population using records in The Health Improvement 
Network (THIN) database (www.thin-uk.com) which added an additional 13 million observation 
years. The observed results closely matched those observed in the internal validation study, adding 
further evidence for the integrity of the QFractureScores approach [16]. The developers of QFracture 
have recently released a new algorithm incorporating additional risk factors such as ethnicity and 
previous fracture based on their analysis of the prospective cohort study, QResearch which has 
improved predictive performance over the original QFracture algorithm [17]. 
 
 
A Comparison of FRAX and QFractureScores  
 
FRAX and QFractureScores were compared using the validation cohort in the original 
QFractureScores study [15]. QFractureScores resulted in better discrimination compared with FRAX 
using the D statistic. The values were 0.11 higher in women, any difference in excess of 0.1 is 
considered important.  The authors attribute the performance of QFractureScores to the fact that 
FRAX uses data from multiple international databases rather than from a single national data source, 
as is the case with the QResearch database. The FRAX algorithm generated an area under the ROC 
curve (AUC) value of 0.845 for female hip fracture and QFractureScores had a value of 0.89 for the 
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same event. Using this data for a direct comparison of FRAX and QFractureScores may however not 
be appropriate due to the difficulties encountered in comparing AUCs between studies, particularly 
when adjustments have not been made for differences in major predictive factors such as age between 
studies [18].  Recent work in an independent UK and Irish based population using only CRFs 
indicated that FRAX and QFractureScores were reasonably well correlated (R=0.857) for hip fracture 
suggesting that both tools could be of value in primary care settings [19]. 
 
In addition to the differences in outcomes predicted, there are methodological differences between the 
two algorithms. DXA measures are not considered in QFractureScores, whereas they are an important 
variable in FRAX. Additionally, mortality is considered in FRAX but not in QFractureScores, death 
as a risk factor becomes increasingly important with age, particularly in the over 80s and this should 
be considered in any comparison of the two models in older subjects. In terms of input factors to the 
algorithm, as shown in Table 1, QFractureScores does not consider prior fracture as it was developed 
in subjects without a prior fracture, which gives the algorithm a different weighting to FRAX. The 
clinically relevant outcomes predicted by the two algorithms also differ as shown in Table 2. 
 
Table 2: Comparison of outcomes 
 FRAX QFractureScores 
Hip Fracture X X 
Clinical Vertebral X X 
Humerus X  
Wrist X  
Distal Radius   X 
 
Current Prognostic Biomarkers 
 
DXA  
 
DXA has been shown to be predictive for hip fracture at the femoral neck with different odds ratios 
depending on the age of the subject, a 50 year old has been shown to have a risk of 3.68 (2.61 – 5.19) 
and an 80 year old to have a risk of 2.28 (2.09 – 2.50) [20]. Incidence rates increase with age, but the 
predictive power of DXA for 10-year hip fracture reduces with age. Additionally, DXA has the 
adoption challenges of cost, availability and effectiveness in women under 65y [21]. This age group 
has been identified as important for taking long term treatment decisions that will have a significant 
impact on future fracture rates; a group DXA is currently unable to support for mass screening 
[21,22].  
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Quantitative Ultrasonography  
 
Quantitative ultrasonography (QUS) is an alternative technique to DXA for assessing BMD and has 
been available since the early 1990s. Hans demonstrated the prognostic power of QUS in women with 
a mean age of 80.4 years over a 2 year follow-up [23]. The relative risk for hip fracture was 2.0 (1.6–
2.4) for broadband ultrasound attenuation (BUA) and 1.9 (1.6–2.4) for speed of sound (SOS) 
compared with 1.9 (1.6–2.4) for BMD as measured by DXA in the same study. There has always been 
a view that QUS measures more aspects of bone structure (e.g. micro-architecture) than just BMD and 
as a result provides some measure of bone quality [24]. Langton et al reported linear regression fit 
(R
2
) values between broadband ultrasound attenuation (BUA) and elasticity (Young’s modulus) in 
calcaneus bone of between 65% and 77%, indicating a relationship between the two values. The 
potential to incorporate some bone quality measures into an overall assessment of fracture risk has 
clear clinical utility [25] and there is now some clinical evidence that QUS is prognostic of hip 
fracture over a 10 year period. A 1 SD decrease in BUA gave a hazard ratio (HR) for non-vertebral 
fracture of 1.414 (1.236 – 1.616) and a 1 SD change in SOS resulted in a HR of 1.359 (1.193 – 1.548) 
[26].  
 
Since the move to measurement of absolute risks for risk assessment there has been a reappraisal of 
the diagnostic potential of QUS. In a recent study of 1,455 participants aged between 64 and 76, 
followed-up over 10.3 years and including 79 fracture cases, an algorithm incorporating both QUS 
and known CRFs including smoking, prior fracture and alcohol intake achieved comparable results to 
DXA. The combination of QUS and CRFs achieved a HR of 2.04 (1.55–2.69) per SD compared with 
a HR of 2.26 (1.74–2.95) for BMD. The authors concluded that in terms of absolute risk, the use of 
QUS is comparable with DXA [27]. The move to absolute risk for assessing future fracture risk 
appears to offer some additional opportunities for QUS to gain wider acceptance but the number of 
long-term prospective studies required to confirm the results of Moayyeri et al will continue to be a 
barrier to its wider acceptance. The adoption of QUS in clinical practice has also been limited due to 
issues with the maintenance of instrument precision, accuracy and reproducibility in practice [23]. 
 
Biochemical Markers  
 
A number of studies have shown that biochemical markers of bone-remodelling are capable of 
predicting fracture risk [28,29]. These biomarkers have the advantage of reflecting global skeletal 
activity whereas BMD measurements assess only a small portion of the skeleton at a specific site. 
Garnero demonstrated that crosslinked C telopeptides of type I collagen (CTX) is prognostic of hip 
fracture in older women, with an odds ratio for hip fracture of 2.2 (1.3–3.6) which was independent of 
bone mass. The use of BMD and CTX in combination generates a higher hip fracture odds ratio of 4.8 
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[30]. While these studies demonstrated the utility of CTX to predict fracture, the patient population 
has limited clinical utility. The EPIDOS study was conducted in an older population (over 74 years of 
age) and the study had a short, 3 year follow-up period. The evidence for CTX’s clinical utility for the 
prevention of future fracture over a longer period and in younger women is still to be developed [29]. 
Other bone turnover markers shown to be predictive include serum osteocalcin, serum procollagen 
type I C propeptide, and urinary deoxypyridinoline, but they all currently lack the required level of 
clinical evidence to justify inclusion in the FRAX algorithm [29]. Biochemical markers have the 
advantage of being easily measured in a serum or urine sample however this also means that issues of 
biological variability can arise. 
 
Genomic Markers   
 
Osteoporosis is a polygenic disease, involving a large variety of gene products implicated in both 
bone modelling and remodelling. A number of candidate genes have already been identified including 
those that code for the following; vitamin D receptor (VDR), oestrogen receptor, insulin growth 
factor, parathyroid hormone and type I collagen. Twin studies have been widely used to assess the 
importance of genotype in the osteoporotic condition, finding that between 60% and 85% of BMD 
variance is genetically determined  [31,32].  Research has also been conducted on non-BMD risk 
factors; Mann et al investigated the genetic influence on non-BMD CRFs including body mass index 
(BMI), age at menopause and smoking history. A statistically significant relationship was found 
between a gene that encodes for collagen type 1 alpha 1 (COL1A1) and BMI and fracture risk [33], 
however the other CRFs were found to be non-significant. An association between the polymorphism 
for transcription factor Sp1 in the gene COL1A1 and bone health has also recently been reported. The 
presence of at least one copy of the T allele was associated with osteoporotic fractures, but not with 
low BMD, in post-menopausal Caucasian women aged 50-70y [34]. The increasing use of whole-
genome studies to investigate disease brings new hope for improved clinical utility with genetic tests, 
but prospective studies will be required to establish a compelling link to future fracture [35]. The 
limitations of the genetic research are that most studies to date have focused on the link between 
genotype and BMD rather than future fracture risk [36]. It is also probable that a prognostic test based 
on whole genome analysis is likely to be prohibitively expensive for mass screening in the foreseeable 
future. 
 
Development of New Prognostic Biomarkers 
 
Due to the limitations of BMD and the existing non-BMD based markers there is a need to identify 
new prognostic markers which could enhance the overall performance of tools like FRAX. 
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Demonstrating that these new biomarkers are predictive of fracture risk rather than correlated with 
DXA T-scores requires the use of prospective study data with substantial follow-up times. Kanis et al 
have discussed the cohorts considered suitable for deriving data for a risk calculator and shown that 
hundreds of thousands of person years are required [1].  
 
The Importance of Cohort Studies 
 
In order to develop a completely novel prognostic marker for osteoporotic fracture risk there is a 
requirement to collect patient samples at baseline and follow the patient for a number of years. Due to 
the low incidence rate of hip fractures in postmenopausal women (less than 5%), cohorts in excess of 
10,000 subjects could be required to ensure sufficient events have occurred over a ten year study, 
making the costs and time commitment for new studies substantial. This is especially the case when 
the women of interest are perimenopausal and therefore the incidence rate of fracture is particularly 
low over the next decade [7]. An alternative, more cost-effective option is to apply a retrospective 
cohort approach using an existing well-established cohort in which samples were collected in the past 
and then followed-up for hip fracture in subsequent years. Osteoporosis cohorts of this type which are 
long established and well known include the Aberdeen Prospective Osteoporosis Screening Study 
[37], and the European Prospective Osteoporosis Study [38]. However, a challenge with retrospective 
cohort approaches is the restriction to existing samples and data already collected which may be sub-
optimal for the new marker of interest. This limitation can mean that data required in the predictive 
algorithm may not have been collected at baseline, either for an individual patient or for the entire 
group. Studies can manage this problem by using multiple imputation for individuals, however for the 
entire cohort it may not be possible to replicate data for the risk factor. The missing risk factor may 
result in different results which should be considered in any overall interpretation of the study. If the 
number of risk factors missing render the retrospective cohort study approach impractical, an 
alternative approach would be to include the new risk factor into a prospective clinical study that 
incorporates treatment.  The advantage of commencing a completely new study is the ability to 
examine any biomarkers of interest and any endpoints of interest. Incorporating the new risk factor as 
an arm in a study such as the Screening of Older Women for Prevention of fracture (SCOOP) study 
[39] may provide an intermediate approach between the lower cost and speed of a solely retrospective 
study and the high costs and long duration of a long-term prospective fracture study. The SCOOP 
study evaluates a FRAX and DXA based screening method compared with standard screening 
methods followed by treatment and the primary outcome is the number of fractures in each arm. This 
five year study will provide evidence of the performance of the predictive algorithm on the most 
important clinical outcome, fractures.  
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In order to enable a retrospective study to be carried out in a timely and cost-effective manner without 
having to test tens of thousands of archived samples, nested case-control designs are attractive. 
Sample types previously collected in published osteoporosis studies have included bone, DXA scores, 
blood, urine, and skin samples [40-42]. Since the incidence rate of hip fracture is less than 3% in the 
age range with most clinical utility, 50 – 70 years of age, the use of case to control ratios of 1:3 or 
more is recommended [43]. As an example of this nested case-control approach envisage a scenario 
where a new technique has been developed which can extract bone quality information from x-ray 
images. If we assume a 1:3 case control ratio is sufficient, rather than conducting a completely new 
study instead archived x-ray images from 100 fracture events and 300 controls could be examined 
retrospectively. These 400 data points could then be evaluated more cost and time effectively than 
using the traditional prospective approach. 
 
 
The developers of the FRAX algorithm developed substantial evidence requirements for the inclusion 
of risk factors including their use in a number of studies, accumulated person-years in trials and 
follow-up durations [7]. For new biomarkers to be accepted into risk calculators, without prohibitive 
barriers to entry, it is proposed that the following acceptance criteria be used: a follow-up time of at 
least five years and independent verification in two cohorts using a training set developed in a 
separate cohort. This approach would allow additional risk factors to be incorporated for applications 
where DXA is not available. 
 
In order to take advantage of the retrospective cohort study approach new prognostic markers must 
make use of stored or archived samples. This means that new prognostic methods which cannot use 
previously archived samples will require prospective studies to be fully validated. This will be a 
significant evidence barrier for the development of some novel techniques. 
 
 
Sample Stability Considerations 
 
Several years of follow-up are required to collect sufficient clinical data for prospective studies and 
when archived samples are used in a study, the effect of the ageing process on the archived samples 
need to be taken into consideration. It is essential to demonstrate that archived samples will yield 
similar or identical results to previous work upon re-analysis or that any changes observed are 
consistent and can be accounted for in subsequent calculations. This question has previously been 
explored in the literature in a limited way; a major challenge is the requirement to evaluate long-term 
storage for each sample type and analyte. UK Biobank has developed a protocol for the collection of 
blood and urine with a view to long-term storage based on a review of the literature and established 
13 
 
the need to freeze samples at particular temperatures for particular applications for long-term storage 
[40]. It is likely that any new biomarker would need to explore the use of accelerated aging on fresh 
biological samples to mimic archived samples stored for several years in order to establish the 
viability of testing the samples for a new analyte. Possible approaches include using calculations such 
as the Arrhenius equation however it is challenging to mimic aging processes that can be measured in 
decades using this process [44]. 
 
 
Performance Evaluation Measures  
 
There has been increased recognition in the recent academic literature that there is a need for 
additional measures to assess the performance of different prognostic risk factors and multivariate risk 
models, beyond what is offered by the receiver operating characteristic (ROC) curve [4]. The ROC 
curve has been observed to perform poorly as a measure of prognostic performance in population 
based cohorts in which the disease has a low prevalence, a graphical example of the increased ROC 
performance observed by the addition of CRFs to BMD is shown in Fig. 1. This is the situation in 
osteoporotic hip fractures where the incidence rate is low, but the consequences for health are very 
serious in terms of increased mortality [6]. McClish has suggested solutions to improve the clinical 
utility by analysing just a portion of the ROC curve [45].  The full area under the ROC curve 
approach was criticised for equally weighting false-positive rates which may not reflect the clinical 
outcomes in a number of conditions. Calibration remains an important evaluation measure for 
predictive models, it assesses the ability of the model to accurately predict the incidence rate for the 
event compared with the rate observed in reality. A graphical example of calibration comparing the 
predictive performance of FRAX and QFracture in a UK cohort has been previously provided (Figs. 2 
and 3) [15], the Hosmer-Lemeshow test is commonly used to report the goodness-of-fit of the 
predicted and observed incidence rates [46]. 
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Figure 1: Receiver operating characteristic curves for the risk score for hip fracture prediction at the 
ages of 50 and 70 years [20]. Image used with permission of the WHO Collaborating Centre for 
Metabolic Bone Diseases, University of Sheffield.  FRAX® is registered to Professor JA Kanis, 
University of Sheffield. 
 
 
Figure 2: Predicted to observed risk of hip fracture using QFractureScore[15] 
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Figure 3: Predicted to observed risk of hip fracture using the FRAX® [15] 
 
New approaches to evaluate the performance of additional clinical markers in a multivariate model 
has been proposed which, move beyond whether a new prognostic test offers good discrimination 
between the cases and controls (as evaluated by the ROC curve) to whether it significantly changes 
the classification of the subject who may be at risk [4]. The addition of risk factors into prognostic 
models can result in small changes in the area under the ROC curve (AUC) which do not reflect the 
changes in risk category that result from the new information [46]. Cook notes that many new 
biomarkers may have clinically relevant odds ratios (OR) (between 1.5 and 2.0) but these will have 
only a modest impact on the ROC curves. New reclassification metrics are able to address the 
weaknesses of these measures in terms of perfect discrimination using ROC curves. It is now being 
argued that these new measures are more important to prognostic models than the traditional ROC 
curve and AUC measure.  
 
More novel techniques which provide additional information on the relative performance of predictive 
models are net benefit analysis [47], decision curve analysis [48], the Pepe method[49], net 
reclassification index (NRI) [46] and integrated discrimination analysis (IDI) [50]. Net benefit 
approaches allow a broader evaluation of the clinical usefulness of a predictive model by 
incorporating information on clinical management strategies, these models can be complex to develop 
and decision curve analysis has the advantage of providing an evaluation of net benefit using a 
simpler model that requires no additional data on costs or treatment effectiveness.  The Pepe method 
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provides additional information on the performance of a model by classifying the subjects based on 
the proportion above and below selected thresholds and their case and non-case status. 
 
Two new measures of prognostic performance, in particular, are gaining popularity: the net 
reclassification index (NRI) and the integrated discrimination improvement (IDI). The NRI is a 
measure which quantifies the number of subjects correctly reclassified as diseased and correctly 
reclassified as healthy based on the addition of a new biomarker.  IDI is similar to NRI but uses 
probabilities rather than risk categories [50]. There is some debate on the most appropriate way to use 
these new measures. Pencina argues that for the evaluation of a new marker, an additional measure. 
IDI, is required, rather than using NRI in isolation. This measure describes the difference between the 
improvement in average sensitivity and any change in average ‘one minus specificity’ and can be seen 
as an alternative to AUC appropriate for use when adding a new marker to a multivariable prediction 
algorithm [50]. 
 
It is notable that the authors of these papers state that these new measures can be used to evaluate 
whether an expensive new biomarker should be introduced from an economic standpoint. However, 
the criteria to evaluate this have not yet been published in detail, Published health economic studies 
typically use odds ratio, relative risk or AUC to evaluate the economic performance of tests [51]. It is 
clear from recent work that the limited impact of some new additive tests on AUC measures restrains 
the ability of clinical practitioners to evaluate cost-effectiveness because AUC is not taking the 
reclassification of subjects into account. A recent study has explored the possibility of evaluating cost-
effectiveness using NRI as an alternative to traditional relative risk based approaches and have 
investigated how measures of discrimination, classification and costs can be linked [52]. Pencina et al 
offers a process which weighs the NRI based on the cost saving when a person moves up in 
classification compared to incurred costs when they move down in classification, caused by 
misclassification. An example would be when a person no longer receives unnecessary treatment as a 
result of reclassification. 
 
These measures have previously been used to explore the performance of cardiac markers and are 
now also being used in osteoporosis studies [53]. In this study, the authors compared a simple BMD 
and age model with the FRAX model using the Cook and Pepe methods in the Study of Osteoporotic 
Fractures. AUC in both models was similar for hip fracture (0.75 versus 0.76), however, the novel 
methods were able to differentiate the predictive models by identifying differences in who is correctly 
and misclassified. A total of 8% of cases were not treated, in error but 18% of non-cases were not 
treated unnecessarily based on an analysis using the Pepe method. 
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Conclusions 
 
Online fracture risk assessment tools offer significant opportunities for novel biomarkers to be used 
for fracture risk prediction. The challenges created by the requirement to demonstrate predictive 
power over time frames in excess of a decade in a disease with a relative low incidence rate is 
challenging, particularly when there are no archived samples to draw on. The recent work with the 
QResearch database indicates that better predictive performance can be achieved by the addition of 
more risk factors, if appropriately validated. While the prevalence of osteoporosis is high, the 
incidence rate of the most damaging event, hip fracture is relatively low, less than 5% per annum in 
the population of interest. The development of new prognostic markers has a significant barrier based 
on the long follow-up time in which events occur. Using retrospective studies with archived samples, 
intervention studies, nested case-control and case-cohort approaches may substantially improve the 
development times for the adoption of new biomarkers. The limited number of archived samples 
available and their stability over long durations will be key considerations in the development of these 
approaches.  
 
A number of alternative prognostic biomarkers have been evaluated to date but none as yet have 
provided the evidence base to supersede DXA. It may be that the way forward now is to use these 
tools in combination with DXA and where cost effective as a pre-screen to select subjects for DXA 
testing. This review has set out some of the considerations required by researchers seeking to 
incorporate new risk factors into the existing prediction algorithms. There is significant scope in the 
field of osteoporosis for the following: increased use of real patient data, increased use of archived 
samples, increased use of endpoints with real clinical utility, i.e. hip fracture, and for prognostic based 
endpoints like NRI and IDI to be applied. These new techniques could ultimately lead to the 
development of a new generation of prognostic tools to improve patient care for sufferers of 
osteoporosis.  
 
Disclosures: None 
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